Preventing the aggregation of toxic proteins in neurodegenerative diseases is both an important biological function and a potential therapeutic strategy. Here, we examine the consequences of O-GlcNAcylation on the aggregation and toxicity of α-synuclein, the aggregating protein in Parkinson's disease.